Company news

Silo Pharma, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15

May 13, 2025

Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories

May 13, 2025

Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study

April 30, 2025

Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study

April 29, 2025

Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's Drug

April 28, 2025

Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer’s Drug

April 27, 2025

Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment

March 25, 2025

Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment

February 25, 2025

Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment

February 17, 2025

Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia

February 10, 2025

Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment

January 21, 2025

Silo Pharma Awarded US Patent for Groundbreaking PTSD Treatment and Prepares for SPC-15 Clinical Trial

January 7, 2025

Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain

January 1, 2025

Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia

December 17, 2024

Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management

November 28, 2024

Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders

November 17, 2024

Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant

October 30, 2024

Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD

September 9, 2024

Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic

August 13, 2024

Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide

August 6, 2024

Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

July 18, 2024

Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15

July 17, 2024

Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic

July 15, 2024

Silo Pharma Announces Exclusive, Global License for Lead Candidate SPC-15 Targeting PTSD and Stress-Induced Anxiety Disorders

July 7, 2024

Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety

June 25, 2024

Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia

June 6, 2024

Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

June 4, 2024

Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety

June 3, 2024

Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention

May 20, 2024

Silo Pharma Announces Positive Results for Intranasal PTSD Treatment

April 22, 2024

Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic

April 9, 2024

Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic

March 19, 2024

Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain

March 17, 2024

Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD

February 27, 2024

Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery

February 13, 2024

Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology

January 31, 2024

Silo Pharma Announces Positive Results in Alzheimer’s Disease Study

January 23, 2024

Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD

January 3, 2024

Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia

December 27, 2023

Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD

November 20, 2023

Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD

November 7, 2023

Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis

October 15, 2023

Silo Pharma Initiates Human Factor Study of SPC-15 for the Treatment of PTSD

October 10, 2023

Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA

September 19, 2023

Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD

September 11, 2023

Silo Pharma Engages Clarivate for Intellectual Property and Patent Management

August 9, 2023

Silo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For Anxiety, PTSD, and Stress-Related Disorders

August 7, 2023

Psychedelics Company Silo Pharma Working On Time-Release And Dosage Ketamine Implant And Topical, Hoping To Deliver Steady Pain Relief For Four Million Fibromyalgia Sufferers

June 23, 2023

Silo Pharma’s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent

June 20, 2023

Silo Pharma Signs Agreement to Develop First-in-Class Ketamine Implant Therapeutic

June 12, 2023

← Newer news releases · Older news releases →

Decks

The 5 newest of 6 decks. Every deck is listed under its year.